Monday , 24 June 2024

Formulation and evaluation of Risperidone sustained release Tablets

P. Suresh1*, U. Venkatesh1, P. Anwar Basha1, G. Sravan reddy2
1St John’s College of Pharmacy, Yemmiganur, Kurnool, Andhra Pradesh
2Hi-Q Herbals, Kothapet, Hyderabad, Telangana

The main aim of the current investigation is to design the sustained release tablets of Risperidone 100mg, used for the treatment of Schizophrenia which can release the drug for 24 hours. Risperidone sustained release tablets with different ratios of polymers Micro crystalline cellulose HPMC K4M, HPMC K 100, Ethyl cellulose, Eudragit RL 100, Sodium CMC, Aerosil by using direct compression technique. Prepared formulation there is no incompatibility between formulation & Excipients by performing FT-IR. The Risperidone along with Excipients powder blends were evaluated for their physical properties like angle of repose, bulk density etc is found to be good and satisfactory. The manufactured tablets were evaluated and finished product quality control tests including dimensions was ranges from F-I to F-XIV 6.02 ± 0.02 to 6.65 ± 0.01, Uniformity weight was ranges from F-I to F-XIV 100 ± 7.5 to 100 ± 7.5 mg, hardness was ranges from F-I to F-XIV 4.0 ± 0.2 to 9.0 ± 0.2 kg/cm2, friability was ranges from F-I to F-XIV 0.032  to 0.218 %, drug content was ranges from F-I to F-XIV 100 ± 7.5 to 100 ± 7.5 mg, Thickness was ranges from F-I to F-XIV  3.482 ± 0.4 mm to 2.966 ± 0.06 mm  and in-vitro drug release. In vitro release data between 1 to 24 hours were considered the F-XIV 93.87 Cumulative % drug release. The drug content of the formulations was found 98.05% for tablets of F-XIV. The percentage axial swelling study of the tablets of the formulations F-III, F-XIII, and F-XIV was performed. The f1 and f2 values for the comparison of release of drugs of first and second trial were found to be 2.53 and 86.86 respectively for the tablets of the formulation F-XIV.

Keywords: Risperidone, sustained release, In-vitro Evaluation, Schizophrenia

Scroll To Top